A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma.
Overview
- Department of Neurosurgery, People’s Hospital Affiliated to Shandong First Medical University, Jinan, China
- Ji’nan (Preparatory) Key Laboratory of Neuromolecular Basis and Clinical Translational Medicine, Jinan, China
- Department of Neurology, People’s Hospital Affiliated to Shandong First Medical University, Jinan, China
- Department of Neurology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
Abstract
The abstract is not reproduced here: the paper's license (CC BY-NC-ND) does not allow it. Read it in the paper, at the publisher or on Europe PMC.
Code
The paper links to its data and to no code of its authors: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE83300, at NCBI GEO; found in the text, “Independent external validation of the…”
Data availability statement
The paper has a data availability statement. Its license (CC BY-NC-ND) does not allow reproducing it here; in short, from what the harvester recognized in it:
- no repository, dataset or request procedure was recognized in it
Read it in the paper: doi.org/10.21037/tcr-2026-0404.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 4 authors, 5 keywords, 62 references.
Cite
This paper
Lu, X., Zhu, S., Si, J., & Qiu, P. (2026). A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma. Translational cancer research, 15(8), 581. https://
BibTeX
@article{lu2026cuproptos
author = {Lu, Xiangdong and Zhu, Siquan and Si, Junzeng and Qiu, Peng},
title = {{A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma}},
journal = {Translational cancer research},
year = {2026},
month = aug,
volume = {15},
number = {8},
pages = {581},
publisher = {AME Publications},
issn = {2218-676X},
doi = {10.21037/
url = {https://
pmid = {42724428},
pmcid = {PMC13559571}
}
RIS
TY - JOUR
AU - Lu, Xiangdong
AU - Zhu, Siquan
AU - Si, Junzeng
AU - Qiu, Peng
TI - A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma
T2 - Translational cancer research
J2 - Transl Cancer Res
PY - 2026
DA - 2026/
VL - 15
IS - 8
SP - 581
SN - 2218-676X
PB - AME Publications
DO - 10.21037/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.21037/
"type": "article-journal",
"title": "A cuproptosis-related lncRNAs-based risk signature for predicting prognosis and immune status in glioma",
"container-title": "Translational cancer research",
"author": [
{
"family": "Lu",
"given": "Xiangdong"
},
{
"family": "Zhu",
"given": "Siquan"
},
{
"family": "Si",
"given": "Junzeng"
},
{
"family": "Qiu",
"given": "Peng"
}
],
"container-title-short":
"volume": "15",
"issue": "8",
"page": "581",
"DOI": "10.21037/
"PMID": "42724428",
"PMCID": "PMC13559571",
"ISSN": "2218-676X",
"publisher": "AME Publications",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
27
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.1111/jcmm.17603
- Identification of cuproptosis-related lncRNAs for prognosis and immunotherapy in glioma.Journal: Journal of cellular and molecular medicineIn common: clinical / translational, other condition, 4 references
- [2] doi:10.1186/s12920-023-01538-3
- Analysis and validation of aging-related genes in prognosis and immune function of glioblastoma.Journal: BMC medical genomicsIn common: NCBI GEO GSE83300, clinical / translational, other condition, 1 reference
- [3] doi:10.1038/s41598-025-07815-8
- CRISPR-Cas9 screening identifies a gene signature predictive of prognosis in glioblastoma.Journal: Scientific reportsIn common: NCBI GEO GSE83300, other condition, 1 reference
- [4] doi:10.1038/s41598-025-10360-z
- SNP rs615552 and lncRNA CDKN2B-AS1 influence brain cancer pathogenesis through multi-omic mechanisms.Journal: Scientific reportsIn common: NCBI GEO GSE83300, other condition
- [5] doi:10.3389/fimmu.2022.1082546 [code]
- Systematic analysis of brain and skull ischemic injury expression profiles reveals associations of the tumor immune microenvironment and cell death with ischemic stroke.Journal: Frontiers in immunologyIn common: other condition, 3 references
- [6] doi:10.1038/s41598-024-54643-3 [code]
- Machine learning-based investigation of regulated cell death for predicting prognosis and immunotherapy response in glioma patients.Journal: Scientific reportsIn common: clinical / translational, other condition, 3 references
- [7] doi:10.1186/s13148-025-01900-5
- A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches.Journal: Clinical epigeneticsIn common: clinical / translational, other condition, 2 references
- [8] doi:10.1186/s12885-023-10714-8
- A novel cuproptosis-related gene signature to predict prognosis in Glioma.Journal: BMC cancerIn common: other condition, 3 references
- [9] doi:10.3389/fphar.2026.1797067
- Network-driven prioritization and functional phenotyping nominate TTC23 as a biomarker-informed target in chlorpromazine repurposing for glioblastoma.Journal: Frontiers in pharmacologyIn common: clinical / translational, other condition, 3 references
- [10] doi:10.3389/fimmu.2022.980378
- SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma.Journal: Frontiers in immunologyIn common: clinical / translational, other condition, 3 references
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.
Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.